𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention

✍ Scribed by Sarah C. Forester; Joshua D. Lambert


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
214 KB
Volume
55
Category
Article
ISSN
1613-4125

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Consumption of green tea (Camellia sinensis) may provide protection against chronic diseases, including cancer. Green tea polyphenols are believed to be responsible for this cancer preventive effect, and the antioxidant activity of the green tea polyphenols has been implicated as a potential mechanism. This hypothesis has been difficult to study in vivo due to metabolism of these compounds and poor understanding of the redox environment in vivo. Green tea polyphenols can be direct antioxidants by scavenging reactive oxygen species or chelating transition metals as has been demonstrated in vitro. Alternatively, they may act indirectly by upregulating phase II antioxidant enzymes. Evidence of this latter effect has been observed in vivo, yet more work is required to determine under which conditions these mechanisms occur. Green tea polyphenols can also be potent pro‐oxidants, both in vitro and in vivo, leading to the formation of hydrogen peroxide, the hydroxyl radical, and superoxide anion. The potential role of these pro‐oxidant effects in the cancer preventive activity of green tea is not well understood. The evidence for not only the antioxidant, but also pro‐oxidant, properties of green tea is discussed in the present review.


📜 SIMILAR VOLUMES


Green tea polyphenol stimulates cancer p
✍ Masami Suganuma; Miki Kurusu; Kaori Suzuki; Emi Tasaki; Hirota Fujiki 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 375 KB 👁 1 views

## Abstract To more clearly understand the molecular mechanisms involved in synergistic enhancement of cancer preventive activity with the green tea polyphenol (−)‐epigallocatechin gallate (EGCG), we examined the effects of cotreatment with EGCG plus celecoxib, a cyclooxygenase‐2 selective inhibito